Figure 3
From: Novel use of FDA-approved drugs identified by cluster analysis of behavioral profiles
Color-coded behavioral profiles. Differences as compared to the DMSO controls were color-coded by conditional formatting to provide an overview of the changes in behavior. The colors are shown in a gradient from green (25% decrease) to red (25% increase). White indicates no change in behavior as compared to the DMSO controls. Note the decrease in activity and the increase in optomotor responses (OMR) in T1A2, which are larvae treated with UK 14,304, an adrenergic alpha-2 receptor agonist. An increase in early activity (1 h), increase in excitability (E), and decrease in OMR was detected in T1A3, which are larvae treated with bromocriptine. Treatments are identified by the Tocris plate number and well number. Differences, as compared to the DMSO control, were tested for significance using Welch’s test with a Bonferroni correction for multiple comparisons, indicating p < 2.6 × 10–4 (0.05/190), p < 5.3 × 10–5 (0.01/190), and p < 5.3 × 10–6 (0.001/190). The figure shows the first two rows of the statistical analysis. The remaining 8 rows did not identify any significant effects. N = number of larvae. Larvae were automatically excluded from the analysis when moving less than 1% of the time during the 3-h imaging experiment. In these cases, N < 48. The effects on behavior and statistics for all 190 compounds are provided in the supplementary information (S5).
